Relief Therapeutics Holding AG (RLFTF)

[mc67]

$RLFTF The APR acquisition is transforming Relief into a fully integrated and diversified biopharmaceutical business.

On June 29, 2021, Relief announced that it had signed and closed the definitive agreement to acquire all outstanding shares of APR Applied Pharma Research S.A., a privately held Swiss biopharmaceutical company with over 25 years’ experience in identifying, developing and commercializing known molecules engineered with drug delivery systems in niche and rare diseases on a global basis.

The acquisition further diversifies Relief's pipeline with both commercial products and clinical-stage programs and provides the initial commercial infrastructure to support future product launches. APR brings to Relief a vibrant R&D organization possessing a lengthy track record of expertise in drug innovation, reformulation and optimization. APR also has a well-respected contract research business, further reflecting the strong R&D capabilities of the APR team and providing Relief additional revenue growth potential.

https://www.relieftherapeutics.com/apr